Expert Interview
Discussing the phase 3 SPLASH study (177Lu-PNT2002) from Point Biopharma, and how it may compare to Pluvicto in mCRPC
Ticker(s): PNT, NVSInstitution: University of Minnesota (formerly Hopkins)
- Associate Director for Translational Research at the Masonic Cancer Center & Director of Genitourinary Oncology Hematology, Oncology, and Transplantation) at the University of Minnesota Medical School.
- Clinical interest is the management of prostate cancer and other genitourinary malignancies.
- Research focuses on developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
